Oct 24, 2023
Executive Summary (Full Report – PDF) Modern formularies initially emerged in the 1980s and 1990s as tools for managing prescription drug costs within healthcare institutions. However, significant changes occurred after the passage of the Affordable Care Act...
Jul 20, 2023
New report analyzes the patient impact of growing coverage restrictions for FDA accelerated approval treatments. WASHINGTON — Patients Rising, a non-profit organization that champions patients with chronic and rare diseases, today released a special report titled CMS...
Jun 2, 2023
In mid-May, the U.S. Supreme Court opted not to take up a patent-infringement case between two pharmaceutical companies – Teva and GlaxoSmithKline (GSK). While it largely went unnoticed among those who are not patent lawyers, IP nerds, or drug companies, the...
May 17, 2023
By Dr. Robert Popovian, Erin Delaney, and Dr. Michael Mandel We may be on the verge of a titanic shift in how drug prices are set. It’s been led by a dramatic decline in insulin prices, but it’s spreading to other brand drugs as well. This new paradigm is the...
Apr 20, 2023
Ohio the latest state to legally challenge the business model of Pharmacy Benefit Mangers (PBMs). Last month, the state’s attorney general filed a landmark lawsuit alleging that Express Scripts and Prime Therapeutics – two of the country’s largest PBMs – illegally...
Nov 17, 2022
Press Contact: Sarah Shelsonsshelson@riesterpublicaffairs.com New framework for the evaluation of rare disease therapies prioritizes patient experiences, feedback, and needs WASHINGTON — Patients Rising, a non-profit organization that advocates on behalf of patients...
